Helen Chow

A phase 2 clinical trial of everolimus plus bicalutamide for castration‐resistant prostate cancer

L. Beckett, R. deVere White, P. Ghosh, 2016, Cancer.

Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy

T. Pugh, H. Berman, Lisa I. Wang, 2021, JNCI cancer spectrum.

Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non–Small-Cell Lung Cancer

L. Beckett, D. Gandara, M. Edelman, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.

Philippe Bédard, L. Siu, A. Hansen, 2019, The oncologist.

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis

Allison P. Heath, Marilyn M. Li, Jena V. Lilly, 2022, Scientific Reports.

Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review

D. Richman, R. Maselli, Tianhong Li, 2023, Frontiers in Oncology.

Abstract P6-01-16: Circulating Tumour DNA (ctDNA) Detection and Dynamics in Patients with Early Breast Cancer (EBC): Results of the Neoadjuvant TRACER cohort

D. Cescon, H. Berman, Philippe Bédard, 2023, Cancer Research.

Inter-laboratory proficiency testing scheme for tumour next-generation sequencing in Ontario: a pilot study.

H. Feilotter, L. Siu, T. Stockley, 2019, Current oncology.

Abstract P3-09-05: Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene

A. Oza, D. Cescon, H. Berman, 2017 .

Association of isocitrate dehydorgenase-1 (IDH-1) mutations with elevated oncometabolite 2-hydroxyglutarate (2HG) in advanced colorectal cancer.

S. Kamel‐Reid, A. Razak, L. Siu, 2016 .